Read news on positive NSCLC with our app.
Read more in the app
Zidesamtinib demonstrates 93% response rate in TKI-naive patients with advanced ROS1-positive NSCLC
Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC